Citations

Clear

912 citation(s) found for "Yu, Caroline".

25. EFFECT OF STEREOTACTIC RADIOSURGERY COMPARED TO WHOLE-BRAIN RADIOTHERAPY FOR LIMITED BRAIN METASTASIS ON LONG TERM COGNITION AND QUALITY OF LIFE: A POOLED ANALYSIS OF NCCTG N107C/CEC.3 AND N0574 (ALLIANCE) RANDOMIZED CLINICAL TRIALS
Klamer, Brett , Brown, Paul D. , Cerhan, Jane H. , Anderson, Keith, Whitton, Anthony , Greenspoon, Jeffrey , Burri, Stuart H., Pollock, Bruce E. , Laack, Nadia N., Ashman, J.B., Bahary, Jean-Paul , Barker, Fred G., Asher, Anthony L. , Palmer, Joshua D. , Ballman, Karla V. , Chung, Caroline , Parney, Ian F. , Stieber, Volker W. , Galanis, Evanthia , Roberge, David

Mayo Clinic

Neuro-Oncology Advances | August 4, 2020 | Volume: 2 | Issue: Supplement_2 | Pages: ii4-ii4

10.1093/noajnl/vdaa073.015 Get It

Abstract PURPOSE We investigated the long term impact of SRS and WBRT in two large prospective phase III trials. METHODS Patients with 1–4 BMs +/- resection were randomized to SRS or WBRT. Cognitive deterioration was a drop of >1 standard deviation from baseline in >2/6 cognitive measures (CM). Quality of life (QOL) scores were scored 0–100 point scale. CM and QOL scores were modeled using baseline adjusted Linear Mixed Models (LMM) with uncorrelated random intercept for subject and random slopes for time. Differences in trend over time between groups and the effect of >2 cognitive scores with >2 SD change from baseline were assessed. RESULTS 88 patients were included with median follow up of 24 months. We observed decreasing CM over time (SRS: 4/6; WBRT: 5/6). Mean CM was significantly higher in SRS for Total recall and Delayed Recall at 3, 6, 9, 12 months. More patients in WBRT arm declined 1 SD in >1 and >2 CM at the 3, 6, 9, and 12 months. A 1 SD decline in >3 CM at 1 year was 21% SRS vs 47% WBRT (p=0.02). SRS had fewer patients with a 2 SD decline in >1 CM at every time point. SRS had fewer patients with a 2 SD decline at >2 and >3 CM. WBRT had lower QOL at 3 months, but switched to SRS having lower QOL at 24 months for PWB, EWB, FWB, FactG, BR, and FactBR (p<0.05). A 2 SD decline in cognition decreased mean FWB by 6.4 units (95% CI: -11, -1.75; p=0.007) and decreased QOL by 5.1 units (95% CI: -7.7, -2.5; p<0.001). CONCLUSIONS We report the first pooled prospective study demonstrating the long term outcomes of patients with BMs after cranial radiation. WBRT was associated with worse cognitive outcomes. Impaired cognition is associated with worse QOL.
Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons
Mohan, Radhe , Liu, Amy , Brown, Paul D. , Mahajan, Anita , Dinh, Jeffrey, Chung, Caroline , McAvoy, Sarah , McAleer, Mary Frances , Ghia, Amol J. , Zhu, Cong , Sulman, Erik P. , Heimberger, Amy B. , McGovern, Susan L. , Ellsworth, Susannah G. , Grosshans, David R. , Sulman, Erik P , Lin, Steven H. , Li, Jing , Groot, John de , Heimberger, Amy B. , Grassberger, Clemens , Shih, Helen A.

Mayo Clinic

Neuro-Oncology | July 31, 2020 | Volume: 23 | Issue: 2 | Pages: 284-294

10.1093/neuonc/noaa182 | PMID 32750703 Get It

Abstract Background We investigated differences in radiation-induced grade 3+ lymphopenia (G3+L), defined as an absolute lymphocyte count (ALC) nadir of <500 cells/µL, after proton therapy (PT) or X-ray (photon) therapy (XRT) for patients with glioblastoma (GBM). Methods Patients enrolled in a randomized phase II trial received PT (n = 28) or XRT (n = 56) concomitantly with temozolomide. ALC was measured before, weekly during, and within 1 month after radiotherapy. Whole-brain mean dose (WBMD) and brain dose-volume indices were extracted from planned dose distributions. Univariate and multivariate logistic regression analyses were used to identify independent predictive variables. The resulting model was evaluated using receiver operating characteristic (ROC) curve analysis. Results Rates of G3+L were lower in men (7/47 [15%]) versus women (19/37 [51%]) (P < 0.001), and for PT (4/28 [14%]) versus XRT (22/56 [39%]) (P = 0.024). G3+L was significantly associated with baseline ALC, WBMD, and brain volumes receiving 5‒40 Gy(relative biological effectiveness [RBE]) or higher (ie, V5 through V40). Stepwise multivariate logistic regression analysis identified being female (odds ratio [OR] 6.2, 95% confidence interval [CI]: 1.95‒22.4, P = 0.003), baseline ALC (OR 0.18, 95% CI: 0.05‒0.51, P = 0.003), and whole-brain V20 (OR 1.07, 95% CI: 1.03‒1.13, P = 0.002) as the strongest predictors. ROC analysis yielded an area under the curve of 0.86 (95% CI: 0.79–0.94) for the final G3+L prediction model. Conclusions Sex, baseline ALC, and whole-brain V20 were the strongest predictors of G3+L for patients with GBM treated with radiation and temozolomide. PT reduced brain volumes receiving low and intermediate doses and, consequently, reduced G3+L.
Evidence for Environmental–Human Microbiota Transfer at a Manufacturing Facility with Novel Work-related Respiratory Disease
Wu, Benjamin G. , Kapoor, Bianca , Cummings, Kristin J. , Stanton, Marcia, Nett, Randall J. , Kreiss, Kathleen, Abraham, Jerrold L. , Colby, Thomas V. , Franko, Angela, Green, Francis H. Y. , Sanyal, Soma, Clemente, José C. , Gao, Zhan , Coffre, Maryaline, Meyn, Peter, Heguy, Adriana , Borbet, Timothy C. , Koralov, Sergei B. , Tallaksen, Robert J. , Wendland, Douglas, Bachelder, Vance D., Boylstein, Randy, Cox‐Ganser, Jean M. , Virji, M. Abbas , Crawford, Judith A., Edwards, Nicole , Veillette, Marc , Warren, Krista, Lundeen, Sarah, Blaser, Martin J. , Segal, Leopoldo N. , Koralov, Sergei B , Blaser, Martin J , Segal, Leopoldo N , Li, Yonghua , Sulaiman, Imran , Park, Ju‐Hyeong , Duchaine, Caroline

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | July 16, 2020 | Volume: 202 | Issue: 12 | Pages: 1678-1688

10.1164/rccm.202001-0197oc | PMID 32673495 Get It

Abstract Rationale Workers’ exposure to metalworking fluid (MWF) has been associated with respiratory disease. Objectives As part of a public health investigation of a manufacturing facility, we performed a cross-sectional study using paired environmental and human sampling to evaluate the cross-pollination of microbes between the environment and the host and possible effects on lung pathology present among workers. Methods Workplace environmental microbiota were evaluated in air and MWF samples. Human microbiota were evaluated in lung tissue samples from workers with respiratory symptoms found to have lymphocytic bronchiolitis and alveolar ductitis with B-cell follicles and emphysema, in lung tissue samples from control subjects, and in skin, nasal, and oral samples from 302 workers from different areas of the facility. In vitro effects of MWF exposure on murine B cells were assessed. Measurements and Main Results An increased similarity of microbial composition was found between MWF samples and lung tissue samples of case workers compared with control subjects. Among workers in different locations within the facility, those that worked in the machine shop area had skin, nasal, and oral microbiota more closely related to the microbiota present in the MWF samples. Lung samples from four index cases and skin and nasal samples from workers in the machine shop area were enriched with Pseudomonas, the dominant taxa in MWF. Exposure to used MWF stimulated murine B-cell proliferation in vitro, a hallmark cell subtype found in the pathology of index cases. Conclusions Evaluation of a manufacturing facility with a cluster of workers with respiratory disease supports cross-pollination of microbes from MWF to humans and suggests the potential for exposure to these microbes to be a health hazard.
Optic Disc Classification by Deep Learning versus Expert Neuro‐Ophthalmologists
Newman, Nancy J. , Najjar, Raymond P. , Vasseneix, Caroline , Xu, Xinxing , Ting, Daniel, Milea, Leonard, Kim, Dong Hyun , Yang, Hee Kyung , Hamann, Steffen, Chen, John J. , Liu, Yong , Wong, Tien Yin , Miléa, Dan , Group, for the BONSAI (Brain and Optic Nerve Study with Artificial Intelligence) Study, Aung, Tin , Kim, Dong Hyun , Milea, Dan , Chen, John J , Wong, Tien Y , Biousse, Valérie , Ting, Daniel Shu Wei , Hwang, Jeong‐Min , Hamann, Steffen , Group, for the BONSAI (Brain and Optic Nerve Study with Artificial Intelligence) Study

Mayo Clinic

Annals of Neurology | July 4, 2020 | Volume: 88 | Issue: 4 | Pages: 785-795

10.1002/ana.25839 | PMID 32621348 Get It

ObjectiveTo compare the diagnostic performance of an artificial intelligence deep learning system with that of expert neuro‐ophthalmologists in classifying optic disc appearance.MethodsThe deep learning system was previously trained and validated on 14,341 ocular fundus photographs from 19 international centers. The performance of the system was evaluated on 800 new fundus photographs (400 normal optic discs, 201 papilledema [disc edema from elevated intracranial pressure], 199 other optic disc abnormalities) and compared with that of 2 expert neuro‐ophthalmologists who independently reviewed the same randomly presented images without clinical information. Area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity were calculated.ResultsThe system correctly classified 678 of 800 (84.7%) photographs, compared with 675 of 800 (84.4%) for Expert 1 and 641 of 800 (80.1%) for Expert 2. The system yielded areas under the receiver operating characteristic curve of 0.97 (95% confidence interval [CI] = 0.96–0.98), 0.96 (95% CI = 0.94–0.97), and 0.89 (95% CI = 0.87–0.92) for the detection of normal discs, papilledema, and other disc abnormalities, respectively. The accuracy, sensitivity, and specificity of the system's classification of optic discs were similar to or better than the 2 experts. Intergrader agreement at the eye level was 0.71 (95% CI = 0.67–0.76) between Expert 1 and Expert 2, 0.72 (95% CI = 0.68–0.76) between the system and Expert 1, and 0.65 (95% CI = 0.61–0.70) between the system and Expert 2.InterpretationThe performance of this deep learning system at classifying optic disc abnormalities was at least as good as 2 expert neuro‐ophthalmologists. Future prospective studies are needed to validate this system as a diagnostic aid in relevant clinical settings. ANN NEUROL 2020;88:785–795
Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders
Shekhar, Skand , Copacino, Caroline E., Hannah‐Shmouni, Fady , Barrera, Francisco J. , Hannah-Shmouni, Fady , Hall, Janet Elizabeth

Mayo Clinic

Annals of the National Academy of Medical Sciences (India) | June 25, 2020 | Volume: 56 | Issue: 02 | Pages: 112-115

10.1055/s-0040-1713346 | PMID 33082620 Get It

AbstractCoronavirus disease 2019 (COVID-19) has affected millions of people across the world but disproportionately and severely affects persons with metabolic disorders such as obesity, diabetes mellitus, and hypertension. In this brief review, we discuss the pathways of immune dysregulation that may lead to severe COVID-19 in persons with metabolic conditions.
Lysosomal degradation ensures accurate chromosomal segregation to prevent chromosomal instability
Almacellas, Eugènia , Pelletier, Joffrey , Day, Charles , Ambrosio, Santiago, Tauler, Albert , Mauvezin, Caroline , Day, Charles A

Mayo Clinic

Autophagy | June 23, 2020 | Volume: 17 | Issue: 3 | Pages: 796-813

10.1080/15548627.2020.1764727 | PMID 32573315 Get It

Perception of barriers to research among internal medicine physician hospitalists by career stage
Dugani, Sagar B. , Geyer, Holly L. , Maniaci, Michael J. , Burton, M. Caroline , Maniaci, Michael J , Dugani, Sagar B

Mayo Clinic

Hospital Practice | June 8, 2020 | Volume: 48 | Issue: 4 | Pages: 206-212

10.1080/21548331.2020.1779537 | PMID 32510254 Get It

Description and validation of a simple histological nerve tissue scoring system for nerve allografts
Bulstra, Liselotte F. , Hundepool, Caroline A. , Shin, Delaney M., Shin, Alexander Y. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

Microsurgery | June 7, 2020 | Volume: 40 | Issue: 6 | Pages: 686-691

10.1002/micr.30614 | PMID 32506477 Get It

AbstractBackgroundIn nerve allograft development, currently used subjective histological scoring systems to evaluate nerve structure in experimental studies are not uniform and have not been validated.The aim of this study was to describe and validate a simple, fast and inexpensive method to compare structural properties of nerve allografts on a histological level.Materials and methodsA total of 113 histological sections of rat (sciatic nerves) and human peripheral nerve segments (thoracodorsal and long thoracic nerve for motor and sural for sensory nerve) treated with various decellularization protocols were analyzed. Slides were stained with Hematoxylin & Eosin (H&E), Toluidine Blue and Laminin. A subjective scoring system using a 5‐point scale was used to score each nerve section by four independent researchers. For validation of this score both inter‐ and intra‐rater reliability were calculated using the Intraclass Correlation Coefficient (ICC).ResultsOverall, an excellent correlation between the different observers was found for the Toluidine Blue (ICC = 0.919, 95% CI: 0.891–0.941), H&E (ICC = 0.9, 95% CI: 0.865–0.927) and Laminin staining (ICC = 0.897, 95% CI: 0.860–0.926). Intra‐rater reliability was good for all three staining techniques (ICC >0.8).ConclusionThis study demonstrates the validity of this simple scoring system to evaluate nerve structure after different processing protocols. All three evaluated staining techniques can reliably be used for both rat and human nerve tissue. We believe this method is suitable to compare different processing techniques to create processed nerve allografts, especially when the average scores of multiple raters are used.
Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas
Boxerman, Jerrold L. , Quarles, C. Chad , Hu, Leland , Gerstner, Elizabeth R. , Smits, Marion , Barboriak, Daniel P. , Huang, Raymond, Wick, Wolfgang , Weller, Michael , Kalpathy–Cramer, Jayashree , Shankar, Lalitha , Jacobs, Paula , Chung, Caroline , Bent, Martin J. van den , Chang, Susan M. , Yung, Wai Kuen, Wen, Patrick Y. , Rosen, Bruce R. , Arons, David F., Kingston, Ann E, Sandak, David, Wallace, M. Z., Musella, Al , Haynes, Chas, Weller, Michael , van den Bent, Martin J , Boxerman, Jerrold L , Wick, Wolfgang , Smits, Marion , Barboriak, Daniel P , Erickson, Bradley J. , Kaufmann, Timothy J. , Galanis, Evanthia , Chang, Susan Marina , Yung, W K Al, Cloughesy, Timothy F. , Wen, Patrick Yung , Gilbert, Mark R. , Ellingson, Benjamin M. , Schmainda, Kathleen M

Mayo Clinic

Neuro-Oncology | June 3, 2020 | Volume: 22 | Issue: 9 | Pages: 1262-1275

10.1093/neuonc/noaa141 | PMID 32516388 Get It

Abstract Despite the widespread clinical use of dynamic susceptibility contrast (DSC) MRI, DSC-MRI methodology has not been standardized, hindering its utilization for response assessment in multicenter trials. Recently, the DSC-MRI Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition issued an updated consensus DSC-MRI protocol compatible with the standardized brain tumor imaging protocol (BTIP) for high-grade gliomas that is increasingly used in the clinical setting and is the default MRI protocol for the National Clinical Trials Network. After reviewing the basis for controversy over DSC-MRI protocols, this paper provides evidence-based best practices for clinical DSC-MRI as determined by the Committee, including pulse sequence (gradient echo vs spin echo), BTIP-compliant contrast agent dosing (preload and bolus), flip angle (FA), echo time (TE), and post-processing leakage correction. In summary, full-dose preload, full-dose bolus dosing using intermediate (60°) FA and field strength-dependent TE (40–50 ms at 1.5 T, 20–35 ms at 3 T) provides overall best accuracy and precision for cerebral blood volume estimates. When single-dose contrast agent usage is desired, no-preload, full-dose bolus dosing using low FA (30°) and field strength-dependent TE provides excellent performance, with reduced contrast agent usage and elimination of potential systematic errors introduced by variations in preload dose and incubation time.
Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey
Hurley, Patricia A. , Kim, Edward S. , Nowakowski, Grzegorz S. , Schilsky, Richard L. , Hurley, Patricia , Waterhouse, David , Harvey, R. Donald , Levit, Laura A. , Klepin, Heidi D. , Mileham, Kathryn Finch , Schenkel, Caroline , Davis, Courtney , Bruinooge, Suanna S.

Mayo Clinic

JCO Oncology Practice | May 12, 2020 | Volume: 16 | Issue: 7 | Pages: 417-421

10.1200/op.20.00275 | PMID 32396491 Get It

The coronavirus disease 2019 (COVID-19) pandemic has disrupted all aspects of clinical care, including cancer clinical trials. In March 2020, ASCO launched a survey of clinical programs represented on its Cancer Research Committee and Research Community Forum Steering Group and taskforces to learn about the types of changes and challenges that clinical trial programs were experiencing early in the pandemic. There were 32 survey respondents; 14 represented academic programs, and 18 represented community-based programs. Respondents indicated that COVID-19 is leading programs to halt or prioritize screening and/or enrollment for certain clinical trials and cease research-only visits. Most reported conducting remote patient care where possible and remote visits and monitoring with sponsors and/or contract research organizations (CROs); respondents viewed this shift positively. Numerous challenges with conducting clinical trials were reported, including enrollment and protocol adherence difficulties with decreased patient visits, staffing constraints, and limited availability of ancillary services. Interactions with sponsors and CROs about modifying trial procedures were also challenging. The changes in clinical trial procedures identified by the survey could serve as strategies for other programs attempting to maintain their clinical trial portfolios during the COVID-19 pandemic. Additionally, many of the adaptations to trials made during the pandemic provide a long-term opportunity to improve and transform the clinical trial system. Specific improvements could be expanded use of more pragmatic or streamlined trial designs, fewer clinical trial–related patient visits, and minimized sponsor and CRO visits to trial programs.